Médecine

Paramédical

Autres domaines


S'abonner

Survival and functional results after a mean follow-up of 9 years with the Ceragyr® highly congruent mobile-bearing TKA - 21/05/15

Doi : 10.1016/j.otsr.2015.01.016 
J. Cournapeau a, , S. Klouche a, T. Bauer a, b, P. Hardy a, b
a Hôpitaux Universitaires Paris Île-de-France Ouest, AP–HP, 92100 Boulogne-Billancourt, France 
b Université de Versailles Saint-Quentin-en-Yvelines, UFR des Sciences de la Santé, 78035 Versailles, France 

Corresponding author. Tel.: +33 6 82 64 51 66.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Introduction

Fixed-bearing total knee arthroplasty (TKA) implants have excellent long-term survival. Mobile-bearing implants were developed to reduce bone–implant interface stresses and polyethylene insert wear. The primary objective of this study was to analyze the survival rate of a highly congruent mobile-bearing TKA implant (Ceragyr®) in patients having a minimum follow-up of 7years. We hypothesized that the survival rate would be 95–100% at that time point.

Patients and methods

A single-center prospective study included all the patients operated for a primary TKA procedure with a Ceragyr® implant between 2000 and 2003. All the implants were cemented. Patellar resurfacing was not carried out systematically, but could be carried out secondarily in cases of persistent anterior knee pain. Clinical and radiological data were collected before the surgery, at 3months postoperative, at 1year and then at a minimum follow-up of 7years. The primary endpoint was the overall revision-free survival rate. Secondary endpoints were the survival without mechanical failure, IKS scores, knee range of motion and implant positioning.

Results

One hundred and thirty-four patients (143 Ceragyr® TKA cases) were included; 9 patients (10 TKA) were lost to follow-up (6.7%) and the remaining 125 patients (133 TKA) were contacted. At the final review, 7 of the 133 TKA cases (5.3%) had been revised (6 men, 1 women; P=0.002), 2 (1.5%) because of mechanical failure and 5 (3.8%) because of an infection. The overall revision-free survival rate was 94.8% [95% CI: 89.3–97.5]; survival was 98.4% [95% CI: 93.8–99.6] with mechanical failure as an endpoint. An in-person assessment was conducted on 76 patients (80 TKA cases) (49 women; 27 men) who had an average age of 70.3±8.4years at the time of the arthroplasty procedure. The patella had been resurfaced during the initial procedure in 49 cases, and was either not resurfaced or secondarily resurfaced in 31 cases. The average follow-up was 8.7±1.1years. The IKS score had significantly improved relative to the preoperative values (P<0.00001). Knee flexion and the IKS knee score remained stable over time (P>0.05). Patients who underwent patella resurfacing during the initial TKA procedure had better clinical results (P=0.03).

Conclusion

After a minimum follow-up of 7years, the overall revision-free survival rate for the Ceragyr® was 94.8%; the survival was 98.4% with mechanical failure as an endpoint. The results were stable over time.

Level of evidence

IV, retrospective study of prospectively collected data.

Le texte complet de cet article est disponible en PDF.

Keywords : Total knee arthroplasty, Mobile-bearing TKA, Highly congruent, Ceragyr®


Plan


© 2015  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 101 - N° 4

P. 455-460 - juin 2015 Retour au numéro
Article précédent Article précédent
  • Long-term outcomes of primary constrained condylar knee arthroplasty
  • P. Cholewinski, S. Putman, L. Vasseur, H. Migaud, A. Duhamel, H. Behal, G. Pasquier
| Article suivant Article suivant
  • No demonstrable benefit for coronal alignment outcomes in PSI knee arthroplasty: A systematic review and meta-analysis
  • A. Mannan, T.O. Smith, C. Sagar, N.J. London, P.J.A. Molitor

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement ou un achat à l’unité.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.